Industry

BioXpedia A/S and BioSkryb Genomics Announce European Partnership to Provide Groundbreaking, Single-Cell, Multiomic Analysis for Novel Target Identification and Therapeutic Development

This new partnership brings high-resolution, single-cell whole genome and whole transcriptome analysis to Europe. This partnership will enable novel insights and deep cellular characterization required in the evaluation, creation, and validation of new generation biologics and therapeutics in targeted disease management. DURHAM, N.C. & AARHUS, Denmark–(BUSINESS WIRE)–#CRISPR—BioSkryb Genomics, a pioneer in developing scientifically advanced single-cell … [Read more…]

More than 1.5 Billion Women Worldwide Lack Essential Health Screenings

Hologic Global Women’s Health Index finds widespread barriers to preventive care and a growing gap in women’s well-being between high- and low-income countries MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX #Gallup–More than 1.5 billion women worldwide lack screenings for cancer, heart disease, diabetes or sexually transmitted diseases/infections – even though these conditions together affect billions of women. The finding … [Read more…]

Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck

NERVIANO, Italy–(BUSINESS WIRE)–Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293. … [Read more…]

Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

Not intended for UK- or Canada-based media NMS-293 is a next generation, orally available, brain-penetrant PARP1 selective inhibitor NMS-293 is currently studied in Phase I as monotherapy for the treatment of patients with BRCA-mutated tumors and in combination with temozolomide in recurrent glioblastoma Next generation PARP1 selective inhibitors could fill a significant unmet patient need … [Read more…]

Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

Not intended for US-, Canada- or UK-based media NMS-293 is a next generation, orally available, brain-penetrant PARP1 selective inhibitor NMS-293 is currently studied in Phase I as monotherapy for the treatment of patients with BRCA-mutated tumors and in combination with temozolomide in recurrent glioblastoma Next generation PARP1 selective inhibitors could fill a significant unmet patient … [Read more…]

CORRECTING and REPLACING Yuluka Health’s Animal Product Line Is Connecting Its Holistic Wellness Products with Top Equestrians

MIAMI–(BUSINESS WIRE)–Please replace the release dated September 20, 2022, with the following corrected version due to multiple revisions. The updated release reads: YULUKA HEALTH’S ANIMAL PRODUCT LINE IS CONNECTING ITS HOLISTIC WELLNESS PRODUCTS WITH TOP EQUESTRIANS Yuluka Health Inc. is a global company with a strong social conscience that prioritizes the health and well-being of … [Read more…]

S2 Genomics Announces New Distribution Partnership to Advance Single Cell Research for the Singulator™ 100 System with Proteigene in France

LIVERMORE, Calif.–(BUSINESS WIRE)–S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for life science applications, announced today that it has entered into a distribution agreement with Proteigene for the promotion, sales, and support of S2’s Singulator™ 100 System and associated products for single-cell genomics and cell biology applications in France. … [Read more…]

Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO

BERKELEY, Calif.–(BUSINESS WIRE)–Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer, announced today an expansion of its Board of Directors and executive leadership team. Anne Phillips, MD, FRCPC joins Carmot’s Board and Heather Turner, J.D., joins … [Read more…]

IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC

POTOMAC, Md.–(BUSINESS WIRE)–#IGC–India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer’s disease.” The original patent application was initiated … [Read more…]

BioBam Releases OmicsBox 2.2, The Latest Update of its Bioinformatics Software Solution

VALENCIA, Spain–(BUSINESS WIRE)–BioBam announced last week the release of OmicsBox 2.2. This new version of BioBam’s bioinformatics solution offers new Single Cell and Long Read Data Analysis Features among other platform improvements. These new additions allow the researchers to use the latest sequencing technologies for their genomics and transcriptomics studies. Dr. Stefan Götz, CEO said: … [Read more…]